Compare ERO & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | TWST |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2021 | 2018 |
| Metric | ERO | TWST |
|---|---|---|
| Price | $30.47 | $67.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $36.50 | ★ $46.88 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $51.94 | $18.91 |
| Revenue Next Year | $2.43 | $15.07 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $12.79 | $23.30 |
| 52 Week High | $39.80 | $69.20 |
| Indicator | ERO | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 66.47 |
| Support Level | $27.82 | $41.85 |
| Resistance Level | $32.62 | N/A |
| Average True Range (ATR) | 1.61 | 4.26 |
| MACD | 0.26 | 1.45 |
| Stochastic Oscillator | 67.70 | 85.46 |
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.